Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Clinical trial NCT06809140 · RECRUITING
Trial details
- NCT number
- NCT06809140
- Sponsor
- Matthew Galsky
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-07
- Primary completion
- 2027-11-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.